Legal Frameworks For Compulsory Licensing And Access To Essential Medicines
1. Conceptual Overview
(A) What is Compulsory Licensing?
- Compulsory licensing (CL) allows a government to authorize a third party to produce a patented product without the consent of the patent holder.
- Under the TRIPS Agreement (Article 31), countries can issue CL to protect public health.
- Commonly used to improve access to essential medicines like HIV/AIDS, cancer drugs, or vaccines.
(B) Why It Matters
- Balances patent rights with public health needs.
- Ensures medicines are affordable and available.
- Important in pandemics or high-cost drug situations.
2. Legal Frameworks
(1) International Law
- TRIPS Agreement (1994):
- Article 31 allows CL under certain conditions (mostly for public non-commercial use).
- Doha Declaration (2001) emphasized flexibility for public health emergencies.
(2) Indian Patent Law
- Indian Patents Act, 1970 (amended 2005)
- Section 84: Any person can apply for CL after 3 years from patent grant.
- Section 92: Government can issue CL in cases of national emergency or public interest.
- Section 100: CL for government use or export to countries lacking manufacturing capacity.
(3) US Law
- The US allows government use licenses under 28 U.S.C. § 1498.
- Rarely invoked, but recognized as a public health tool.
(4) Policy Principles
- Affordability and access over profit in life-saving drugs.
- CL is a last-resort mechanism when voluntary licensing fails.
3. Key Legal Issues
- Eligibility for CL: Must show unmet demand or unaffordability.
- Scope and Duration: Limited to public health needs.
- Royalty Payment: Reasonable remuneration to patent holder.
- Judicial Oversight: Courts review government decisions for reasonableness.
- International Tension: Patent holders may challenge CL in WTO or domestic courts.
4. Case Laws (Detailed Analysis)
1. Novartis AG v. Union of India
Facts:
- Novartis challenged the rejection of a patent for Glivec, a cancer drug, claiming “incremental innovation”.
Holding:
- The Supreme Court upheld Section 3(d), which prevents evergreening patents.
- Incremental changes that do not enhance efficacy are not patentable.
Relevance:
- Reduced the barrier to generic production.
- Paved the way for cheaper alternatives under CL provisions.
2. Bayer Corporation v. Union of India
Facts:
- Natco Pharma applied for CL on Bayer’s patented cancer drug Nexavar (sorafenib) due to high cost.
Holding:
- India’s Controller General granted first-ever CL in 2012.
- Natco had to pay 6% royalty to Bayer.
Key Points:
- Public health justification: High cost made access impossible for most patients.
- Encouraged generic competition.
3. Merck Sharp & Dohme Corp v. Government of Brazil
Facts:
- Brazil threatened CL for Merck’s HIV drugs to negotiate lower prices.
Holding:
- CL was avoided after price negotiations, but the threat demonstrated the legal and strategic use of CL under Brazilian patent law and TRIPS flexibilities.
Relevance:
- CL serves both as legal tool and bargaining power for public health access.
4. Canada v. Apotex Inc
Facts:
- Canadian government issued a CL for an HIV drug under the Jean Chrétien Pledge to Africa Act for export.
Holding:
- WTO-compliant CL allowed export to least-developed countries without violating international patent law.
Key Points:
- Demonstrates public health-oriented CL for global access.
- Reinforces the Doha Declaration’s intent.
5. Zentiva v. Czech Republic
Facts:
- Government authorized CL for a cardiovascular drug due to national health crisis.
Holding:
- European courts supported proportional use of CL for public health.
Relevance:
- Confirms CL is legally sustainable in emergencies, even in high-IP jurisdictions.
6. Roche v. Cipla
Facts:
- Cipla challenged Roche’s HIV drug patents indirectly by producing generics for India and Africa.
Outcome:
- Settlement allowed Cipla to supply cheaper generics.
- Demonstrated market-driven CL pressure even before formal licensing.
7. Thailand Ministry of Public Health v. Abbott Laboratories
Facts:
- Thailand issued CL for antiretroviral drugs to reduce HIV/AIDS mortality.
Holding:
- Justified under national emergency/public health.
- Abbott received royalty, CL improved drug accessibility dramatically.
5. Emerging Legal Principles
- Public Health Overrides IP
- Consistent with TRIPS and Doha Declaration.
- Reasonable Royalty Must Be Paid
- Balances patent rights with public interest.
- CL Is Evidence- and Need-Based
- Governments must justify unaffordability or lack of availability.
- Judicial Scrutiny Ensures Fairness
- Courts check proportionality, procedural correctness, and reasonableness.
- Global Precedent Supports Flexibility
- Countries like Brazil, Canada, Thailand demonstrate WTO-compliant CL.
6. Regulatory Implications
- Governments should maintain transparent CL guidelines.
- International collaboration ensures affordable access without IP violations.
- Monitoring ensures CL is time-limited and proportional.
7. Conclusion
Compulsory licensing and access to essential medicines:
- Are legally grounded in both domestic and international law.
- Case law shows a clear trend: public health takes priority over patent monopolies.
- Properly implemented, CL reduces mortality, ensures affordability, and remains WTO-compliant.
RELATED Blog
comments